DLD

DLD encodes dihydrolipoyl dehydrogenase (E3), the FAD-dependent oxidoreductase that catalyzes NAD⁺-dependent oxidation of dihydrolipoamide as the shared E3 subunit of the pyruvate dehydrogenase complex, α-ketoglutarate dehydrogenase complex, branched-chain α-keto acid dehydrogenase complexes, and the glycine cleavage system, thereby occupying a central node in mitochondrial oxidative metabolism (PMID:28579060, PMID:2188967). The α-KGDH complex containing DLD also translocates to the nucleus, where it associates with KAT2A to supply succinyl-CoA for histone H3 lysine 79 succinylation, linking DLD-dependent metabolism to epigenetic gene regulation and tumor cell proliferation (PMID:29211711). DLD is specifically required for cystine deprivation-induced ferroptosis, functioning upstream of mitochondrial iron accumulation and lipid peroxidation through its regulation of α-KGDH activity (PMID:31931284). Loss-of-function DLD mutations cause dihydrolipoamide dehydrogenase deficiency—manifesting as lactic acidosis, Leigh syndrome, and multi-organ pathology—through impaired enzymatic activity, disrupted E2 binding, and enhanced ROS generation (PMID:28579060, PMID:23290025).

1. 1990 High

   Defining the modular architecture of the E2 subunits that scaffold DLD/E3 into functional multienzyme complexes established how substrate channeling occurs within the dehydrogenase complexes and identified the E3-binding domain as the structural determinant for DLD recruitment.

   Evidence Biochemical reconstitution and domain-deletion analysis of dihydrolipoamide acyltransferases in vitro

   PMID:2188967

   Open questions at the time

   • Structural basis for E3–E2 interaction at atomic resolution was not resolved
   • Regulation of DLD/E3 incorporation into different complexes in vivo was not addressed
2. 2003 High

   Characterizing PDK/PDP-mediated phosphorylation–dephosphorylation of the pyruvate dehydrogenase complex revealed how E3-dependent catalytic flux is regulated across metabolic states, establishing that DLD activity is indirectly controlled by isoform-specific kinase and phosphatase activities acting on E1.

   Evidence Kinase/phosphatase kinetic assays and phosphorylation-site specificity analysis of PDC regulation

   PMID:12676647

   Open questions at the time

   • Whether analogous regulatory phosphorylation mechanisms operate on the KGDH and BCKDH complexes housing DLD was not resolved
   • Direct post-translational modifications on DLD itself were not characterized
3. 2013 Medium

   Identification of novel compound heterozygous DLD mutations (p.I353T/p.G136del) causing Leigh syndrome with 9–29% residual E3 activity demonstrated that partial loss of DLD function is sufficient to cause severe neurodegeneration, bridging genotype to clinical phenotype.

   Evidence Enzymatic assay of E3 activity in patient fibroblasts with molecular confirmation of compound heterozygosity

   PMID:23290025

   Open questions at the time

   • Single family study; genotype–phenotype correlation across larger cohorts was not established
   • Structural consequences of these specific mutations were not resolved at atomic level
4. 2017 High

   Systematic biochemical analysis of disease-causing DLD variants revealed that pathogenic mutations not only reduce catalytic activity but also impair E2-binding affinity and enhance ROS generation, establishing that DLD dysfunction has dual consequences—metabolic insufficiency and oxidative stress—both contributing to disease pathogenesis.

   Evidence Enzymatic activity, ROS generation, FAD binding, and E2-binding affinity assays across multiple pathogenic hE3 variants

   PMID:28579060

   Open questions at the time

   • Whether ROS generation by mutant DLD is a primary driver or secondary consequence in vivo remains unresolved
   • Tissue-specific vulnerability to DLD mutations was not mechanistically explained
5. 2017 High

   Discovery that the α-KGDH complex containing DLD translocates to the nucleus and supplies succinyl-CoA for KAT2A-mediated histone H3K79 succinylation fundamentally expanded DLD's functional scope from a metabolic enzyme to an epigenetic regulator affecting gene expression and tumor proliferation.

   Evidence Subcellular fractionation, co-immunoprecipitation, ChIP-seq, crystal structure of KAT2A–succinyl-CoA, site-directed mutagenesis, in vivo tumor growth assays

   PMID:29211711

   Open questions at the time

   • Signal or mechanism directing α-KGDH nuclear import is unknown
   • Whether DLD catalytic activity is required for the nuclear function or whether DLD serves a structural role in the nuclear complex is not distinguished
   • Scope of genes regulated by this mechanism is incompletely mapped
6. 2020 High

   Demonstrating that DLD is specifically required for cystine deprivation-induced ferroptosis—through regulation of KGDH activity, mitochondrial membrane potential, and mitochondrial iron accumulation—placed DLD at a mechanistic nexus between TCA cycle metabolism and regulated cell death.

   Evidence siRNA/shRNA knockdown with cDNA rescue, lipid ROS and mitochondrial iron quantification, KGDH activity assays, and mouse xenograft models in head and neck cancer cells

   PMID:31931284

   Open questions at the time

   • How DLD/KGDH activity promotes mitochondrial iron accumulation mechanistically is unclear
   • Whether DLD's role in ferroptosis extends beyond cystine deprivation contexts or to non-cancer cells is not established

• Key unresolved questions include the mechanism of α-KGDH nuclear translocation, whether DLD has direct post-translational regulatory inputs, and how DLD-dependent ROS generation versus metabolic insufficiency contribute differentially to tissue-specific pathology in DLD deficiency.
• Nuclear import signal/mechanism for the DLD-containing α-KGDH complex is unknown
• Direct post-translational modifications of DLD itself are uncharacterized
• Mechanistic basis for tissue-specific vulnerability in DLD deficiency is not resolved